Improving Patient Selection for BPH Medical and Surgical Therapy Through a Deeper Understanding of Prostate Cellular and Molecular Biology
Abstract
This article explores how a deeper understanding of prostate cellular and molecular biology can improve treatment selection for benign prostatic hyperplasia (BPH). Current strategies rely on prostate size and symptoms, but BPH is highly heterogeneous in tissue composition. Recent research shows that identifying glandular versus stromal-dominant phenotypes using tools like prostate-specific antigen density, MRI, and ultrasound may predict treatment response. Personalized approaches based on these findings could improve outcomes and reduce side effects. The study advocates for a shift from symptom-based to phenotype-driven BPH management, paving the way for precision medicine in urology. BPH is an age-related enlargement of the prostate transition zone, which often results in progressive worsening of obstructive lower urinary tract symptoms (LUTS) and risk of acute urinary retention. By 2030, the US population aged more than 80 years is projected to double, with an estimated 11 million men affected by LUTS, mostly because of BPH. As the population ages and comorbidities worsen, BPH/LUTS patients will continue to outpace the availability of providers. Surgical management for BPH/LUTS has diversified dramatically over the last 10 years with a proliferation of minimally invasive surgical techniques (MISTs) designed to be performed under outpatient care and to minimize time to recovery. On the other hand, medical management has remained largely the same for decades. Current…
Read the paper
Related studies
- Luteolin rescues postmenopausal osteoporosis elicited by OVX through alleviating osteoblast pyroptosis via activating PI3K-AKT signaling
- Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues
- Luteolin Inhibits Dexamethasone‐Induced Osteoporosis by Autophagy Activation Through miR‐125b‐5p/SIRT3/AMPK/mTOR Axis, an In Vitro and In Vivo Study
- Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes
- Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI‐RS 2023
- Chylomicron-mimicking supramolecular nano emulsion for oral luteolin delivery against hyperuricemia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.